Pcn32 - The Effectiveness and Safety of Switching From Orginal Filgrastim to Biosimilar Filgrastim in Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia: A Retrospective Cohort Study

Rabayah, A.A. Al; Hammoudeh, Suzan S; Mashni, Ola; Hanoun, Esraa; Qasem, Wafa; Momani, Deema

doi:10.1016/j.jval.2018.09.114

Cited by 1 publication

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an oncology study, Al Rabayah et al (2018) also found an increase in both the frequency and duration of hospitalizations among patients who switched to a biosimilar in comparison to those who remained on the reference biologic (15.6% vs 12.6% and 7 days vs 6.4 days, respectively, follow-up period not specified) [ 6 ].…”

Section: Resultsmentioning

confidence: 99%

“…While these studies were scarce, they provided a better understanding of the savings or costs that were associated with the switch from the reference biologic to the biosimilar drug. Specifically, three studies reported on HCRU differences [6,33,34], three studies reported on cost differences [35][36][37], and one study reported on differences in both HCRU and overall costs [32]. With regards to HCRU, all studies concluded that NMS was associated with a significant or numerical increase in HCRU among patients who underwent originator-tobiosimilar NMS [6,[32][33][34].…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, three studies reported on HCRU differences [6,33,34], three studies reported on cost differences [35][36][37], and one study reported on differences in both HCRU and overall costs [32]. With regards to HCRU, all studies concluded that NMS was associated with a significant or numerical increase in HCRU among patients who underwent originator-tobiosimilar NMS [6,[32][33][34]. Interestingly, there was a notable difference between studies in terms of outpatient visits associated with NMS, where this was greater for the study by Tarallo et 2017) found that a NMS from originator etanercept or infliximab to the biosimilar in rheumatic patients generated an overall increase in total costs to patients in comparison to remaining on the originator (p = 0.046 in Phillips (2017), unreported in Peral (2018) and Tarallo (2019)) [32,36,37].…”

Section: Discussionmentioning

confidence: 99%

“…Interestingly, all four of these studies reported an increase in HCRU with originator-to-biosimilar NMS, three of which were focused on rheumatology and the other on oncology. More specifically, they found that NMS can be associated with increased medical visits, medical services such as imaging, phone consultations, and emergency room (ER) visits, in addition to hospitalizations [6,[32][33][34].…”

Section: Healthcare Resource Utilization (Hcru)mentioning

confidence: 99%

“…Important biologic drugs include hormones, hematopoietic growth factors, thrombolytic agents, cytokines, therapeutic enzymes, and antibodies [1]. Biologics are used in the treatment of rheumatological diseases, such as rheumatoid arthritis (RA), and gastrointestinal diseases, such as Crohn's disease (CD) and ulcerative colitis (UC) [2][3][4][5]; they can also be used to treat patients suffering from other chronic conditions in the areas of dermatology, hepatology, oncology, and growth development [6][7][8][9]. For this reason, the discovery of biological therapies have made a substantial clinical impact on the Canadian healthcare system.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

Hillhouse¹,

Mathurin

Parison

et al. 2021

Adv Ther

View full text Add to dashboard Cite

Introduction To save costs to the healthcare system, forced non-medical switch (NMS) policies that cut drug coverage for originator biologics and fund only less expensive biosimilars are being implemented. However, costs related to the impact of NMS on healthcare resource utilization (HCRU) must also be considered. This study aims to summarize the evidence on the economic impact of an originator-to-biosimilar NMS. Methods A systematic literature review (SLR) was conducted. Publications reporting on HCRU or costs associated with originator-to-biosimilar NMS in the real-world setting were searched in MEDLINE and EMBASE from January 2008 to February 2020. In addition to hand searching the reference lists of relevant publications and SLRs, key conference websites, PubMed, and various government sites were also searched for the 2 years preceding the search (2018–2020). Results A total of 1845 citations were identified, of which 49 were retained for data extraction. Most studies reporting on the HCRU associated with NMS reported on post-NMS HCRU alone without a comparison pre-NMS. However, four studies described a difference in HCRU (i.e., investigations pre- vs post-switch or between non-switchers vs switchers), all of which reported a relative increase in HCRU, including laboratory testing, imaging, medical visits, and hospitalizations, amongst patients who underwent an originator-to-biosimilar NMS. Most studies reporting on the costs associated with NMS reported significant savings following NMS on the basis of drug costs alone. However, four studies specifically reporting on the difference of costs following originator-to-biosimilar NMS all demonstrated an increase in HCRU-related costs associated with NMS (increase in HCRU-related costs of 4–37% or 148–2234 2020 Canadian dollars). Conclusion Amongst the studies that reported on the difference in HCRU pre- vs post-switch or between non-switchers and switchers, all showed an increase in HCRU and related costs associated with NMS, suggesting that the expected overall savings due to less costly drug prices may be reduced as a result of an increase in HCRU and its associated costs post-switch. Nevertheless, more real-world studies that include NMS-related healthcare costs in addition to drug costs are needed. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01951-z.

show abstract

Section: Resultsmentioning

confidence: 99%